| Bioactivity | SAH-EZH2, a stable EZH2 α-helical peptide, is an EZH2/EED interaction inhibitor. SAH-EZH2 targets native embryonic ectoderm development (EED), disturbs its interactions with EZH1 and EZH2, and selectively decreases trimethylation of H3K27[1]. |
| Invitro | The selectivity of SAH-EZH2 activity is highlighted by the lack of a SAH-EZH2 effect on the H3K4, H3K9 and H3K36 methyl marks. MLL-AF9 leukemia cells, which are dependent on PRC2, undergo growth arrest and monocyte-macrophage differentiation upon treatment with SAH-EZH2, consistent with observed changes in expression of PRC2-regulated, lineage-specific marker genes[1]. 0 --> SAH-EZH2 相关抗体: |
| Name | SAH-EZH2 |
| CAS | 1453222-26-8 |
| Shortening | Ac-FSSNR-{(S)-2-(4ʹ-pentenyl)Ala}-KIL-{(S)-2-(4ʹ-pentenyl)Ala}-RTQILNQEWKQRRIQPV (Covalent bridge: Ala6-Ala10) |
| Formula | C155H256N48O40 |
| Molar Mass | 3431.99 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Woojin Kim, et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol. 2013 Oct;9(10):643-50. |
SAH-EZH2
CAS: 1453222-26-8 F: C155H256N48O40 W: 3431.99
SAH-EZH2, a stable EZH2 α-helical peptide, is an EZH2/EED interaction inhibitor. SAH-EZH2 targets native embryonic ecto
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.